What is SNAP-8?
SNAP-8 (INCI: Acetyl Octapeptide-3) is a synthetic octapeptide developed by Lipotec (now Lubrizol) as an extended version of Argireline (Acetyl Hexapeptide-3). Both peptides are based on the N-terminal sequence of SNAP-25, the SNARE complex component responsible for docking neurotransmitter vesicles at the synaptic membrane.
SNAP-8 extends the Argireline sequence by two amino acids, providing a longer fragment that may bind to more sites on the SNARE complex, potentially improving inhibition efficacy relative to the shorter hexapeptide.
Important: SNAP-8 is a cosmetic ingredient, not a pharmaceutical. The information on this page is offered for educational and cosmetic formulation reference purposes. It is not medical advice.
SNAP-8 vs. Argireline: what changes
Both share the same core mechanism (competitive SNAP-25 N-terminal mimicry), but SNAP-8 extends the fragment from 6 to 8 amino acids:
| Argireline | SNAP-8 | |
|---|---|---|
| INCI name | Acetyl Hexapeptide-3 | Acetyl Octapeptide-3 |
| Chain length | 6 amino acids | 8 amino acids |
| SNARE binding | N-terminal fragment | Extended N-terminal fragment |
| Claimed improvement | Baseline | ~30% more effective than Argireline per Lipotec data |
| Commercial concentration supplied | Typically 5–10% solution | Typically 5–10% solution |
The two peptides are often formulated together (3–5% each) because their complementary binding positions on the SNARE complex may produce additive inhibition — a common strategy in “botox-alternative” product development.
Proposed mechanism of action
SNAP-8 competitively displaces the N-terminal portion of endogenous SNAP-25 from the SNARE complex. When SNAP-25 cannot integrate into the complex, the vesicle-docking machinery that triggers acetylcholine release is impaired. This produces a localized attenuation of muscle contraction signaling.
The extension to 8 amino acids provides additional contact points with the SNARE complex binding interface, which is the proposed basis for enhanced binding affinity relative to Argireline.
What the research says
Lipotec’s published data report a ~26% reduction in wrinkle depth after 28 days at 10% SNAP-8, compared to ~17% for Argireline alone in equivalent split-face conditions. Cell-based assays show decreased neurosecretion in catecholamine release models.
Independent peer-reviewed clinical trials with SNAP-8 as the sole variable are limited. The mechanistic framework (SNARE complex competition) is the same as for Argireline, which has slightly more independent research support. In practice, both ingredients are typically evaluated as part of multi-peptide stacks, making isolated efficacy data sparse.
Typical use in formulations
- Concentration range: 3–10% in finished formulation
- Optimal pH: 4.5–6.5
- Solubility: Water-soluble; supplied as aqueous solution (typically 10% active in water/propanediol)
- Target area: Forehead lines, crow’s feet, glabellar frown lines, perioral lines — all areas where repetitive muscle contraction drives wrinkle formation
- Incompatibilities: High-pH environments (above 7.5) may reduce stability. Same precautions as Argireline regarding strongly cationic actives.
- Synergies: The Argireline + SNAP-8 combination (equal parts, 5% each) is widely used in professional serums. Adding Leuphasyl and/or Syn-ake creates a four-mechanism formula covering presynaptic opioid modulation, SNARE inhibition from two peptides, and postsynaptic receptor competition.
Cosmetic vs. pharmaceutical context
SNAP-8 is marketed as “the next generation of Argireline” or “enhanced botox alternative.” These claims are permissible in cosmetic marketing as inspiration references. Claims of muscle paralysis, nerve blocking, or therapeutic effect must be avoided in product labeling under FDA and EU regulations.
Acceptable: “studied for reduction of expression line appearance.” Not acceptable: “blocks nerve signals” or “provides botox-level results.”
Reported protocol (research reference)
| Reported dose | Typically used at 3–10% concentration in topical formulations. Often combined with Argireline at equal ratios for additive SNARE-inhibition coverage. |
|---|---|
| FDA status | Not FDA approved |